Patent Yard Sign in
Canadian application, no grantCanada

Inhibitors of farnesyl protein transferase

CA 2294530 A1 · Owner: Ding, Charles Z. · Inventors: Ding, Charles Z.; Bhide, Rajeev S.; Leftheris, Katerina

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Disclosed are quinoline and benzazepine derivatives that inhibit farnesylprotein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed June 16, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 16, 2018.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 16, 2020.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJune 16, 1998
GrantedNo grant recorded
Term endedJune 16, 2018
Patent numberCA 2294530 A1
Classification (IPC)C07D233/02 +2 more

Timeline

Timeline From CIPO dates

1999200120032005200720092011201320152017Application filedJune 16, 1998Term endedJune 16, 2018

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.